Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.27% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.27% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 9.27% | -- | |||
| SG&A Expenses | -55.45% | -10.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -41.37% | -12.13% | |||
| Operating Income | 45.43% | 18.64% | |||
| Income Before Tax | 2.70% | 21.36% | |||
| Income Tax Expenses | -72.44% | 13.90% | |||
| Earnings from Continuing Operations | 5.15% | 20.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.15% | 20.49% | |||
| EBIT | 45.43% | 18.64% | |||
| EBITDA | 45.47% | 18.66% | |||
| EPS Basic | 10.17% | 20.27% | |||
| Normalized Basic EPS | 8.33% | 20.00% | |||
| EPS Diluted | 10.17% | 20.27% | |||
| Normalized Diluted EPS | 8.33% | 20.00% | |||
| Average Basic Shares Outstanding | 5.85% | 0.00% | |||
| Average Diluted Shares Outstanding | 5.85% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||